SCHEMBL17486854

SCHEMBL17486854

C=Cc1ccccc1S(=O)(=O)NCCOc1cccc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1B P28222 8/20 0.49
▸ HTR1D P28221 2/20 0.49
▸ SLC6A4 P31645 2/20 0.48
▸ HRH1 P35367 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ NR2E1 Q9Y466 1/20 0.45
▸ GLRA3 O75311 1/20 0.45
▸ GLRB P48167 1/20 0.45
▸ SCN1A P35498 2/20 0.43
▸ SCN2A Q99250 2/20 0.43
▸ SCN3A Q9NY46 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19287439 0.81 HTR1B (0.56) HTR1BHTR1DSLC6A4HRH1KDM4E
SCHEMBL16055874 0.81 GLRA3 (0.53) HTR1BHTR1DSLC6A4HRH1KDM4E
SCHEMBL17486847 0.80 HTR1B (0.56) HTR1BHTR1DSLC6A4HRH1KDM4E
SCHEMBL17486852 0.80 HRAS (0.56) KDM4EALDH1A1KMT2A
SCHEMBL17486849 0.79 GLRA3 (0.51) HTR1BHTR1DSLC6A4HRH1KDM4E
SCHEMBL17486855 0.78 BCHE (0.51) KDM4EALDH1A1HPGDSCN1ASCN2A
SCHEMBL27539264 0.74 CASP1 (0.44) KDM4EALDH1A1HPGDHTR6
SCHEMBL27393985 0.71 RECQL (0.42) KDM4EALDH1A1SCN1ASCN2ASCN3A
SCHEMBL9568512 0.71 SCN1A (0.51) KDM4EALDH1A1SCN1ASCN2ASCN3A
SCHEMBL5289923 0.71 HTR1B (0.77) HTR1BHTR1DSLC6A4HRH1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745319-B2 Irreversible covalent inhibitors of the GTPase K-Ras G12C ARAXES PHARMA LLC (US) 2017-08-29 — — US disclosed
US-9745319-B2 Irreversible covalent inhibitors of the GTPase K-Ras G12C ARAXES PHARMA LLC (US) 2017-08-29 — — US disclosed
US-20160031898-A1 IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C ARAXES PHARMA LLC 2016-02-04 — — US disclosed
US-20160031898-A1 IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C ARAXES PHARMA LLC 2016-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031898-A1 IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C KRAS, HRAS, NRAS HTR1B 4722/4885HTR1D 4798/4885SLC6A4 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback